Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Attention-deficit hyperactivity disorder (ADHD) and glial integrity: S100B, cytokines and kynurenine metabolism--effects of medication.

Oades RD, Dauvermann MR, Schimmelmann BG, Schwarz MJ, Myint AM.

Behav Brain Funct. 2010 May 28;6:29. doi: 10.1186/1744-9081-6-29.

2.
3.

Attention-deficit hyperactivity disorder (ADHD) and glial integrity: an exploration of associations of cytokines and kynurenine metabolites with symptoms and attention.

Oades RD, Myint AM, Dauvermann MR, Schimmelmann BG, Schwarz MJ.

Behav Brain Funct. 2010 Jun 9;6:32. doi: 10.1186/1744-9081-6-32.

4.

Serum concentrations of kynurenines in adult patients with attention-deficit hyperactivity disorder (ADHD): a case-control study.

Aarsland TI, Landaas ET, Hegvik TA, Ulvik A, Halmøy A, Ueland PM, Haavik J.

Behav Brain Funct. 2015 Nov 5;11(1):36. doi: 10.1186/s12993-015-0080-x.

5.

Changes in serum levels of kynurenine metabolites in paediatric patients affected by ADHD.

Evangelisti M, De Rossi P, Rabasco J, Donfrancesco R, Lionetto L, Capi M, Sani G, Simmaco M, Nicoletti F, Villa MP.

Eur Child Adolesc Psychiatry. 2017 Dec;26(12):1433-1441. doi: 10.1007/s00787-017-1002-2. Epub 2017 May 19.

PMID:
28527020
6.

Serum brain-derived neurotrophic factor, glial-derived neurotrophic factor, nerve growth factor, and neurotrophin-3 levels in children with attention-deficit/hyperactivity disorder.

Bilgiç A, Toker A, Işık Ü, Kılınç İ.

Eur Child Adolesc Psychiatry. 2017 Mar;26(3):355-363. doi: 10.1007/s00787-016-0898-2. Epub 2016 Aug 25.

PMID:
27561780
7.

Empathy and Facial Expression Recognition in Children With and Without Attention-Deficit/Hyperactivity Disorder: Effects of Stimulant Medication on Empathic Skills in Children with Attention-Deficit/Hyperactivity Disorder.

Gumustas F, Yilmaz I, Yulaf Y, Gokce S, Sabuncuoglu O.

J Child Adolesc Psychopharmacol. 2017 Jun;27(5):433-439. doi: 10.1089/cap.2016.0052. Epub 2017 Mar 23.

PMID:
28332851
8.

Grey matter volumes in treatment naïve vs. chronically treated children with attention deficit/hyperactivity disorder: a combined approach.

Villemonteix T, De Brito SA, Kavec M, Balériaux D, Metens T, Slama H, Baijot S, Mary A, Peigneux P, Massat I.

Eur Neuropsychopharmacol. 2015 Aug;25(8):1118-27. doi: 10.1016/j.euroneuro.2015.04.015. Epub 2015 Apr 18.

PMID:
25934396
9.
10.

Abnormal executive function in attention deficit hyperactivity disorder: the effect of stimulant medication and age on spatial working memory.

Barnett R, Maruff P, Vance A, Luk ES, Costin J, Wood C, Pantelis C.

Psychol Med. 2001 Aug;31(6):1107-15.

PMID:
11513378
11.

The cognitive-energetic model: an empirical approach to attention-deficit hyperactivity disorder.

Sergeant J.

Neurosci Biobehav Rev. 2000 Jan;24(1):7-12. Review.

PMID:
10654654
12.

Developmental trajectories of brain volume abnormalities in children and adolescents with attention-deficit/hyperactivity disorder.

Castellanos FX, Lee PP, Sharp W, Jeffries NO, Greenstein DK, Clasen LS, Blumenthal JD, James RS, Ebens CL, Walter JM, Zijdenbos A, Evans AC, Giedd JN, Rapoport JL.

JAMA. 2002 Oct 9;288(14):1740-8.

PMID:
12365958
13.

An examination of the effects of stimulant medication on response inhibition: a comparison between children with and without attention deficit hyperactivity disorder.

Brackenridge R, McKenzie K, Murray GC, Quigley A.

Res Dev Disabil. 2011 Nov-Dec;32(6):2797-804. doi: 10.1016/j.ridd.2011.05.027. Epub 2011 Jun 22.

PMID:
21700419
14.

Executive function and attention deficit hyperactivity disorder: stimulant medication and better executive function performance in children.

Kempton S, Vance A, Maruff P, Luk E, Costin J, Pantelis C.

Psychol Med. 1999 May;29(3):527-38.

PMID:
10405075
15.

Methylphenidate normalises activation and functional connectivity deficits in attention and motivation networks in medication-naïve children with ADHD during a rewarded continuous performance task.

Rubia K, Halari R, Cubillo A, Mohammad AM, Brammer M, Taylor E.

Neuropharmacology. 2009 Dec;57(7-8):640-52. doi: 10.1016/j.neuropharm.2009.08.013. Epub 2009 Aug 26.

PMID:
19715709
16.

The effects of gender and numbers of depressive episodes on serum S100B levels in patients with major depression.

Yang K, Xie GR, Hu YQ, Mao FQ, Su LY.

J Neural Transm (Vienna). 2008 Dec;115(12):1687-94. doi: 10.1007/s00702-008-0130-8. Epub 2008 Nov 4.

PMID:
18982242
17.

A lack of association between elevated serum levels of S100B protein and autoimmunity in autistic children.

Al-Ayadhi LY, Mostafa GA.

J Neuroinflammation. 2012 Mar 16;9:54. doi: 10.1186/1742-2094-9-54.

18.

Dissociation in response to methylphenidate on response variability in a group of medication naïve children with ADHD.

Johnson KA, Barry E, Bellgrove MA, Cox M, Kelly SP, Dáibhis A, Daly M, Keavey M, Watchorn A, Fitzgerald M, McNicholas F, Kirley A, Robertson IH, Gill M.

Neuropsychologia. 2008 Apr;46(5):1532-41. doi: 10.1016/j.neuropsychologia.2008.01.002. Epub 2008 Jan 12.

PMID:
18289615
19.

Increased serum S100B in elderly, chronic schizophrenic patients: negative correlation with deficit symptoms.

Schmitt A, Bertsch T, Henning U, Tost H, Klimke A, Henn FA, Falkai P.

Schizophr Res. 2005 Dec 15;80(2-3):305-13. Epub 2005 Jun 17.

PMID:
15964742
20.

Attention deficit/hyperactivity disorder and medication with stimulants in young children: a DTI study.

de Luis-García R, Cabús-Piñol G, Imaz-Roncero C, Argibay-Quiñones D, Barrio-Arranz G, Aja-Fernández S, Alberola-López C.

Prog Neuropsychopharmacol Biol Psychiatry. 2015 Mar 3;57:176-84. doi: 10.1016/j.pnpbp.2014.10.014. Epub 2014 Nov 14.

PMID:
25445066

Supplemental Content

Support Center